CPC G16B 45/00 (2019.02) [C12Q 1/6886 (2013.01); G06F 16/285 (2019.01); G06F 17/18 (2013.01); G16B 5/00 (2019.02); G16B 5/20 (2019.02); G16B 20/00 (2019.02); G16B 25/10 (2019.02); G16B 30/00 (2019.02); G16B 40/00 (2019.02); G16B 40/20 (2019.02); G16B 40/30 (2019.02); G16B 50/00 (2019.02); G16B 50/30 (2019.02); G16H 10/20 (2018.01); G16H 20/00 (2018.01); G16H 20/10 (2018.01); G16H 20/40 (2018.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01); G16H 50/50 (2018.01); G16H 50/70 (2018.01); G16H 70/20 (2018.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01)] | 16 Claims |
1. A method comprising:
using at least one computer hardware processor to perform:
obtaining sequencing data about at least one biological sample of a subject;
accessing, in at least one database, biomarker information indicating a distribution of values for each biomarker in at least a reference subset of a plurality of biomarkers, each biomarker in the reference subset being associated with at least one candidate therapy, wherein the at least one candidate therapy is associated with a clinical trial, the reference subset of the plurality of biomarkers including a first biomarker associated with a first gene and a second biomarker associated with a second gene different from the first gene, and the biomarker information including a first distribution of values for the first biomarker and a second distribution of values for the second biomarker;
determining, using the sequencing data, un-normalized biomarker scores for at least some biomarkers in the reference subset of the plurality of biomarkers, the un-normalized biomarker scores including a first un-normalized biomarker score for the first biomarker and a second un-normalized biomarker score for the second biomarker;
determining normalized biomarker scores for the at least some biomarkers in the reference subset of the plurality of biomarkers at least in part by adjusting the un-normalized biomarker scores for the at least some biomarkers to a common scale, the adjusting comprising adjusting the first and second un-normalized biomarker scores to the common scale using the first and second distributions of values respectively;
identifying the subject as a member of one or more cohorts using the normalized biomarker scores for the subject, wherein each of the one or more cohorts is associated with a positive or negative outcome of the at least one candidate therapy; and
outputting an indication of the one or more cohorts in which the subject is identified as a member.
|